A Phase 3 Randomized, Double-blind Study of Ianalumab (VAY736) Versus Placebo in Addition to Eltrombopag in Patients With Primary Immune Thrombocytopenia (ITP) Who Had an Insufficient Response or Relapsed After First Line Steroid Treatment (VAYHIT2)
Latest Information Update: 23 May 2025
At a glance
- Drugs Eltrombopag (Primary) ; Ianalumab (Primary)
- Indications Idiopathic thrombocytopenic purpura
- Focus Registrational; Therapeutic Use
- Acronyms VAYHIT2
- Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
Most Recent Events
- 30 Apr 2025 According to Novartis media release, the data read out from this study is expected in H2 25.
- 18 Apr 2025 Planned End Date changed from 28 Apr 2028 to 10 Apr 2028.
- 02 Apr 2025 Planned End Date changed from 19 May 2028 to 28 Apr 2028.